Fate Therapeutics (FATE) Receivables - Accured (2019 - 2026)

Fate Therapeutics has reported Receivables - Accured for 8 years, with the latest figure at $800000.0 in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Accured fell 60.0% year-over-year to $800000.0; the trailing twelve-month figure through Mar 2026 stood at $800000.0 (down 60.0% YoY), and the FY2025 full-year result was $700000.0, down 66.67% from the prior year.
• Receivables - Accured for Q1 2026 stood at $800000.0, up from $700000.0 in the prior quarter.
• The five-year high for Receivables - Accured was $2.1 million in Q4 2024, with the low at $1000.0 in Q2 2022.
• Historically, Receivables - Accured has averaged $1.1 million across 5 years, with a median of $1.0 million in 2022.
• Annual changes were most pronounced in 2022 — Receivables - Accured tumbled 99.95% — and 2024, when it surged 154445.45%.
• Fate Therapeutics' Receivables - Accured stood at $800000.0 in 2022, then increased by 12.5% to $900000.0 in 2023, then soared by 133.33% to $2.1 million in 2024, then slumped by 66.67% to $700000.0 in 2025, then increased by 14.29% to $800000.0 in 2026.
• The last three Receivables - Accured figures came in at $800000.0 (Q1 2026), $700000.0 (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.